Veeva Systems Inc. (VEEV) SEC Filings & Earnings Calls
EquiReason read 14 Veeva Systems Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-27 — Veeva filed its quarterly report (10-Q) for the period ended July 31, 2026, disclosing revenue growth rates and ongoing risks related to CRM platform migration and competitive pres.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
- Market cap
- 52.3B
- P/E TTM
- 52.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
27 Aug 202610-QVeeva filed its quarterly report (10-Q) for the period ended July 31, 2026, disclosing revenue growth rates and ongoing risks related to CRM platform migration and competitive pressure.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue Growth Rate · FY2026 | 16.0% | |
| Subscription Revenue Growth Rate · FY2026 | 17.0% | |
| Top 10 Customer Revenue Concentration · FY2026 | 28.0% |
Risks flagged
CRM Platform Migration Failure
“The migration of our Veeva CRM customers requires time and expense, which may be significant. These migration processes are complex and we cannot be certain that we will be successful.” · word for word
Customer Loss to Salesforce
“Salesforce, our primary CRM competitor, has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions and a number of our customers have informed us of their intent to move to Salesforce as their CRM provider.” · word for word
Revenue Growth Deceleration
“In our fiscal years ended January 31, 2026, 2025, and 2024, our total revenues grew by 16%, 16%, and 10% respectively... subscription revenues grew by 17%, 20%, and 10% respectively.” · word for word
26 Aug 20268-K · 2.02Veeva Systems reported Q2 FY2027 total revenues of $928.0M (+18% YoY), subscription revenues $766.8M (+16% YoY), and raised full-year guidance.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q2-2027 | $928M | +18% y/y |
| Subscription revenues · Q2-2027 | $767M | +16% y/y |
| Non-GAAP operating income · Q2-2027 | $416M | +18% y/y |
| GAAP net income · Q2-2027 | $273M | +37% y/y |
| Non-GAAP net income · Q2-2027 | $387M | +16% y/y |
| Non-GAAP diluted EPS · Q2-2027 | $2.35 | +18% y/y |
Guidance
FY27 total revenues raised to $3,682-3,687M from prior; Q3 FY27 total revenues $932-935M; FY27 non-GAAP OI ~$1,640M; FY27 non-GAAP diluted EPS ~$9.21; Q3 FY27 non-GAAP OI $417-420M; Q3 FY27 non-GAAP diluted EPS $2.33-2.34
Raised full-year revenue and profit guidance after Q2 beat; strong demand and margin expansion.
20 Aug 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Loss of a senior customer-facing executive could temporarily disrupt client relationships, though departure is amicable.
“Mr. Schwenger most recently serving as President and Chief Customer Officer.”
5 Jun 202610-QRevenue $883M (+16% y/y); Subscription Revenue $730M (+15% y/y); Net income $261M (+14% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2027 | $883M | +16% y/y |
| Subscription Revenue · Q1-2027 | $730M | +15% y/y |
| Net income · Q1-2027 | $261M | +14% y/y |
| Net cash provided by operating activities · Q1-2027 | $1.13B | +28% y/y |
| Free cash flow · Q1-2027 | $1.13B | |
| Gross Margin · Q1-2027 | 75.0% | |
| Non-GAAP Operating Income · Q1-2027 | $395M | +13% y/y |
| Non-GAAP Net Income · Q1-2027 | $371M | +13% y/y |
| Non-GAAP Diluted EPS · Q1-2027 | $2.24 | +14% y/y |
| Share Repurchases · Q1-2027 | $221M |
Risks flagged
CRM Migration Risk
“The migration of our Veeva CRM customers will require time and expense, which may be significant. These migration processes are complex and we cannot be certain that we will be successful.” · word for word
Competition from Salesforce
“Salesforce, our primary CRM competitor, has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions and a number of our customers have informed us of their intent to move to Salesforce as their CRM provider.” · word for word
Customer Concentration
“In each of our fiscal years ended January 31, 2026, 2025, and 2024, our top 10 customers accounted for 28% of our total revenues.” · word for word
Dependence on Life Sciences Industry
“Nearly all of our revenues are generated by sales to customers in the life sciences industry.” · word for word
3 Jun 20268-K · 2.02Total Revenues $883M (+16% y/y); Subscription Revenues $730M (+15% y/y); Non-GAAP Operating Income $395M (+13% y/y); Guidance: Full-year revenue guidance raised to $3.635-3.645B; Q2 guidance $902-905M.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q1-2027 | $883M | +16% y/y |
| Subscription Revenues · Q1-2027 | $730M | +15% y/y |
| Non-GAAP Operating Income · Q1-2027 | $395M | +13% y/y |
| Non-GAAP Net Income · Q1-2027 | $371M | +13% y/y |
| Non-GAAP EPS (diluted) · Q1-2027 | $2.24 | +14% y/y |
| GAAP Net Income · Q1-2027 | $261M | +14% y/y |
| GAAP EPS (diluted) · Q1-2027 | $1.57 | +15% y/y |
Guidance
Full-year revenue guidance raised to $3.635-3.645B; Q2 guidance $902-905M.
Raised guidance across all metrics; strong AI momentum and broad-based growth.
Risks flagged
Dependence on AI product adoption for future growth; execution risk on new platforms.
“AI strategy is central to growth; new products like Falcon are in early adopter phase.”
4 May 2026DEF 14AVeeva filed its 2026 proxy statement, disclosing executive compensation, governance updates, and a $2B buyback program.open
Figures in the filing · each found in the filing text
| Net income · FY2026 | $909M |
Risks flagged
CEO compensation controversy
“ISS and Glass Lewis characterized the 2024 option grant to our CEO as outsized and recommended that shareholders vote against the re-election of Mr. Carges and Mr. Ritter.”
Non-compete litigation risk
“We filed a lawsuit against Epic Systems Corporation challenging Epic’s sweeping use of employment non-compete agreements.” · word for word
20 Apr 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Key executive departure; mitigated by transition period and advisor role.
“Departure of General Counsel; successor to be appointed.”
20 Mar 202610-KNumber of customers 1,552; Number of employees 7,928 (+9% y/y); Issued U.S. patents 111open
Figures in the filing · each found in the filing text
| Number of customers · FY2026 | 1,552 | |
| Number of employees · FY2026 | 7,928 | +9% y/y |
| Issued U.S. patents · FY2026 | 111 | |
| Pending patent applications · FY2026 | 164 | |
| International revenue as % of total · FY2026 | 40.0% | |
| Top 10 customer revenue concentration · FY2026 | 28.0% |
Risks flagged
CRM migration risk to Vault CRM
“The migration of our CRM customers to our Vault CRM applications built on our own Veeva Vault platform could cause business disruptions for customers and adversely affect our operating results.” · word for word
Salesforce competition for CRM customers
“Salesforce, our primary CRM competitor, has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions and a number of our customers have informed us of their intent to move to Salesforce as their CRM provider.” · word for word
Cybersecurity breach risk
“If our security measures are breached or compromised or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure, customers may reduce or stop their use of our solutions, and we may incur significant liabilities.” · word for word
Life sciences industry consolidation
“Consolidation within the life sciences industry has accelerated in recent years, and this trend could continue. We have in the past, and may in the future, suffer reductions in user subscriptions or non-renewal of customer subscription orders due to industry consolidation.” · word for word
Drug pricing regulation impact
“Significant changes in drug pricing policy or regulation could result in lower revenues and profits for life sciences companies and reduced demand for our products.” · word for word
4 Mar 20268-K · 2.02Total revenues $836M (+16% y/y); Subscription revenues $708M (+16% y/y); Operating income $246M (+30% y/y); Guidance: Q1 FY2027 revenue guidance $855-858M; non-GAAP operating income $378-381Mearningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q4-2026 | $836M | +16% y/y |
| Subscription revenues · Q4-2026 | $708M | +16% y/y |
| Operating income · Q4-2026 | $246M | +30% y/y |
| Non-GAAP operating income · Q4-2026 | $367M | +19% y/y |
| Net income · Q4-2026 | $244M | +25% y/y |
| Non-GAAP net income · Q4-2026 | $346M | +20% y/y |
| Total revenues (full year) · FY2026 | $3.20B | +16% y/y |
| Subscription revenues (full year) · FY2026 | $2.68B | +17% y/y |
| Non-GAAP operating income (full year) · FY2026 | $1.43B | +24% y/y |
| Non-GAAP net income (full year) · FY2026 | $1.35B | +24% y/y |
Guidance
Q1 FY2027 revenue guidance $855-858M; non-GAAP operating income $378-381M
Guidance raised with strong revenue and margin outlook.
Risks flagged
Dependence on life sciences industry.
“Industry cloud solutions for global life sciences.”
5 Jan 20268-K · 8.01Share repurchase authorization $2.00Bopen
Figures in the filing · each found in the filing text
| Share repurchase authorization · 2026-01-05 | $2.00B |
21 Nov 202510-QVeeva reported Q3 FY2026 results with total revenue +16% YoY, subscription revenue +17% YoY, and net income +27% YoY, while resolving IQVIA litigation.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q3-2026 | $811M | +16% y/y |
| Subscription services revenues · Q3-2026 | $682M | +18% y/y |
| Net income · Q3-2026 | $236M | +27% y/y |
| Operating cash flow · 9M-2026 | $1.31B | +28% y/y |
| Free cash flow · 9M-2026 | $1.29B | +28% y/y |
| Non-GAAP operating income · Q3-2026 | $365M | +20% y/y |
| Non-GAAP net income · Q3-2026 | $345M | +20% y/y |
| Subscription gross margin · Q3-2026 | 86.0% | |
| Professional services gross margin · Q3-2026 | 18.0% | |
| Total gross margin · Q3-2026 | 75.0% |
Risks flagged
CRM Migration Risk
“The migration of our CRM customers to our Vault CRM applications built on our own Veeva Vault platform could cause business disruptions for customers, lead to the loss of our customers to competitors, and adversely affect our operating results.” · word for word
Competition from Salesforce/IQVIA
“Our CRM solutions primarily compete with Salesforce, which has developed a life sciences industry-specific CRM application. IQVIA, which historically offered a competitive CRM solution, has licensed its CRM software to Salesforce and intends to jointly market a CRM solution for life sciences with Salesforce.” · word for word
Customer Concentration
“In our fiscal years ended January 31, 2025, 2024, and 2023, our top 10 customers accounted for 28%, 28%, and 29% of our total revenues, respectively.” · word for word
Data Privacy Regulation
“Increasingly complex regulations relating to privacy, data protection, and cybersecurity are burdensome, may reduce demand for our solutions, and non-compliance may impose significant liabilities.” · word for word
Dependence on Third-Party Infrastructure
“We rely on third-party providers—including Amazon Web Services and Salesforce—for computing infrastructure, secure network connectivity, and other technology-related services needed to deliver our cloud solutions.” · word for word
20 Nov 20258-K · 2.02Total Revenues $811M (+16% y/y); Subscription Services Revenues $682M (+17% y/y); Non-GAAP Operating Income $365M (+20% y/y); Guidance: FY2026 total revenues raised to $3,166-$3,169M; non-GAAP EPS ~$7.93earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q3-2026 | $811M | +16% y/y |
| Subscription Services Revenues · Q3-2026 | $683M | +17% y/y |
| Non-GAAP Operating Income · Q3-2026 | $365M | +20% y/y |
| Non-GAAP Net Income · Q3-2026 | $345M | +20% y/y |
| Non-GAAP Diluted EPS · Q3-2026 | $2.04 | +17% y/y |
| GAAP Operating Income · Q3-2026 | $241M | +33% y/y |
| GAAP Net Income · Q3-2026 | $236M | +27% y/y |
| GAAP Diluted EPS · Q3-2026 | $1.40 | +24% y/y |
| Total Revenues Guidance (FY2026) · FY2026 | $3.17B | |
| Non-GAAP Operating Income Guidance (FY2026) · FY2026 | $1.42B |
Guidance
FY2026 total revenues raised to $3,166-$3,169M; non-GAAP EPS ~$7.93
Raised full-year guidance reflects broad-based strength and confidence in reaching $6B revenue run-rate by 2030.
18 Nov 20258-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Transition risk in accounting function until replacement is named.
“CAO resignation; CFO assumes interim role.”
Veeva Systems Inc. — questions
- What did Veeva Systems Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-27 — Veeva filed its quarterly report (10-Q) for the period ended July 31, 2026, disclosing revenue growth rates and ongoing risks related to CRM platform migration and competitive pressure.
Every figure on this page comes from Veeva Systems Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.